1. Home
  2. NPCE vs RIGL Comparison

NPCE vs RIGL Comparison

Compare NPCE & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NPCE
  • RIGL
  • Stock Information
  • Founded
  • NPCE 1997
  • RIGL 1996
  • Country
  • NPCE United States
  • RIGL United States
  • Employees
  • NPCE N/A
  • RIGL N/A
  • Industry
  • NPCE Medical Specialities
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • NPCE Health Care
  • RIGL Health Care
  • Exchange
  • NPCE Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • NPCE 339.6M
  • RIGL 298.0M
  • IPO Year
  • NPCE 2021
  • RIGL 2000
  • Fundamental
  • Price
  • NPCE $11.15
  • RIGL $19.28
  • Analyst Decision
  • NPCE Buy
  • RIGL Buy
  • Analyst Count
  • NPCE 6
  • RIGL 5
  • Target Price
  • NPCE $14.83
  • RIGL $36.80
  • AVG Volume (30 Days)
  • NPCE 167.9K
  • RIGL 208.8K
  • Earning Date
  • NPCE 05-13-2025
  • RIGL 05-06-2025
  • Dividend Yield
  • NPCE N/A
  • RIGL N/A
  • EPS Growth
  • NPCE N/A
  • RIGL N/A
  • EPS
  • NPCE N/A
  • RIGL 0.99
  • Revenue
  • NPCE $79,906,000.00
  • RIGL $179,278,000.00
  • Revenue This Year
  • NPCE $19.53
  • RIGL $12.53
  • Revenue Next Year
  • NPCE $11.83
  • RIGL $15.68
  • P/E Ratio
  • NPCE N/A
  • RIGL $19.25
  • Revenue Growth
  • NPCE 22.14
  • RIGL 54.71
  • 52 Week Low
  • NPCE $5.45
  • RIGL $7.48
  • 52 Week High
  • NPCE $15.11
  • RIGL $29.82
  • Technical
  • Relative Strength Index (RSI)
  • NPCE 47.58
  • RIGL 57.97
  • Support Level
  • NPCE $10.02
  • RIGL $16.05
  • Resistance Level
  • NPCE $11.76
  • RIGL $17.67
  • Average True Range (ATR)
  • NPCE 0.94
  • RIGL 1.27
  • MACD
  • NPCE 0.02
  • RIGL 0.38
  • Stochastic Oscillator
  • NPCE 45.23
  • RIGL 95.21

About NPCE Neuropace Inc.

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: